GI Dynamics Announces Access to 2017 Annual Meeting of Stockholders and Corporate Update
May 17 2017 - 9:50PM
Business Wire
GI Dynamics®, Inc. (ASX:GID) (the Company) will hold its 2017
Annual Meeting of Stockholders on 22 May 2017, at 6:00 p.m., United
States Eastern Daylight Time, (23 May 2017, at 8:00 a.m.,
Australian Eastern Standard Time) at the offices of Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center,
Boston, MA 02111.
Immediately following the Annual Meeting of Stockholders,
Company management will provide a corporate update.
If not attending in person, the meeting and corporate update can
be accessed through a teleconference line.
Accessing the Annual Meeting of Stockholders and Corporate
Update via the teleconference line:
For those preferring to listen by telephone, please dial-in five
minutes prior to the start of the call. Regional dial-in numbers
are as follows:
United States
callers please dial toll-free (877) 407-6184
Australia
callers please dial toll-free 1 (800) 687-004
United Kingdom
callers please dial toll-free 0 (800) 756-3429
International
callers please dial (201) 389-0877
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier,
the first endoscopically-delivered device therapy approved for the
treatment of type 2 diabetes and obesity. EndoBarrier is not
approved for sale in the United States and is limited by federal
law to investigational use only in the United States. Founded in
2003, GI Dynamics is headquartered in Boston, Massachusetts. For
more information, please visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
our expectations regarding the effect of the CE mark suspension,
our ability to resolve nonconformance issues to the satisfaction of
our notified body, and the timing of any reinstatement of our CE
mark. These forward-looking statements are based on GI Dynamics
management’s current estimates and expectations of future events as
of the date of this announcement. Furthermore, the estimates are
subject to several risks and uncertainties that could cause actual
results to differ materially and adversely from those indicated in
or implied by such forward-looking statements. These risks and
uncertainties include but are not limited to, risks associated with
obtaining funding from third parties; the consequences of stopping
the ENDO trial and the possibility that future clinical trials will
not be successful or confirm earlier results; the timing and costs
of clinical trials; the timing of regulatory submissions; the
timing, receipt and maintenance of regulatory approvals; the timing
and amount of other expenses; the timing and extent of third-party
reimbursement; risks associated with commercial product sales,
including product performance, competition, market acceptance of
products, intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size of
the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170517006469/en/
GI Dynamics, Inc.Investor RelationsUnited
States:Janell Shields, +1-781-357-3246Investor
Relationsinvestor@gidynamics.comorMedia RelationsUnited
States:Nicole Franklin, +1-617-657-1312nfranklin@jpa.com
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2024 to May 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From May 2023 to May 2024